Genital infections.
Explore the source record for details and available documents.
Acquired Immunodeficiency Syndrome↗
Biomedical subjects
A Mindel
Publications and source records attributed to A Mindel.
Randomised controlled trial of adenine arabinoside 5'-monophosphate (ARA-AMP) in chronic hepatitis B virus infection.
A randomised controlled trial was conducted in 29 HBV carriers who had been HBs and HBe antigen positive for more than six months. Fifteen patients were treated with ARA-AMP 10 mg/kg/day given as intramuscular injections 12 hours apart for five days followed by 5 mg/kg/day for 23 days. The 14 controls received no treatment. Serum HBV-DNA polymerase, and HBV-DNA decreased in all patients during therapy. Six treated patients lost serum HBV-DNA polymerase, HBV-DNA and HBeAg, HBsAg concentrations decreased, and five developed anti-HBe. One of these six patients lost HBsAg and developed anti-HBs. No such changes were observed in the control group over a similar 18 month period of observation. A four week course of ARA-AMP inhibits HBV replication and in a significant minority of patients this is long lasting and is associated with a reduced level of inflammatory activity in the liver.
Adult↗
Prophylactic oral acyclovir in recurrent genital herpes.
56 patients with frequently recurring genital herpes were treated in a randomised double-blind trial with either oral acyclovir 200 mg four times a day or placebo for 12 weeks. 29 patients received the drug and 27 the placebo. The mean recurrence rate per month of treatment was 1.4 in the placebo-treated patients and 0.05 in the acyclovir group. Median time to the first recurrence after the start of therapy was 14 days in the placebo group compared with 100 days in the acyclovir group. After the end of treatment the recurrence rate was similar in the two groups. Prophylactic oral acyclovir seems to be an effective treatment for patients with frequently recurring genital herpes.
Acyclovir↗
Infection with Brucella melitensis apparently acquired in the United Kingdom.
A patient with Brucella melitensis presented to a clinic for sexually transmitted diseases. She had unusual clinical signs including polyarthropathy and a tender enlarged spleen. Her disease was apparently acquired in the United Kingdom. The clinical features and immunological aspects of brucellosis are discussed.
Adult↗
Treatment and prevention of herpes genital infection.
The recent introduction of acyclovir for the treatment of genital herpes offers new hope for sufferers of this troublesome and recurrent condition. The results of the published trials with acyclovir in both primary and recurrent genital herpes are reviewed. The results show that acyclovir is a useful drug for the treatment of primary infections, but has a limited role in treating recurrences. Preliminary results with prophylactic oral acyclovir suggest that this form of therapy may be useful in patients with frequent severe recurrences.
Acyclovir↗
Long term oral acyclovir in disseminated mucocutaneous herpes simplex: a case report.
A 24 year old woman with Crohn's disease presented initially with a severe primary genital herpes infection. After the first attack frequent recurrences occurred on the hands, feet, and genitalia. The patient was treated with oral acyclovir for 12 weeks, during which time she had two brief minor recurrences. After treatment was stopped lesions recurred at the same sites.
Acyclovir↗
Antibodies to cytomegalovirus in homosexual and heterosexual men attending an STD clinic.
We studied the prevalence of antibody to cytomegalovirus (CMV) in 262 men (132 homosexual, 20 bisexual, and 108 heterosexual) attending the sexually transmitted diseases (STD) clinic at this hospital. Antibody to CMV at a titre of 1/4 or more was found in 92% of the homosexuals, 80% of the bisexuals, and 56% of the heterosexuals (p less than 0.0001). Among heterosexuals, but not homosexuals, nationality and social class showed a significant association with antibody to CMV. In both heterosexuals and homosexuals a history of gonorrhoea was more common in patients with antibody to CMV than in those without it. A similar finding was seen in heterosexual men with a history of non-specific urethritis (NSU). Using a series of log linear models, sexual orientation was shown to be the most important determinant of antibody to CMV in this population.
Adolescent↗
Genital herpes: hype or hope?
Explore the source record for details and available documents.
Attitude to Health↗
Should homosexuals be vaccinated against hepatitis B virus? Cost and benefit assessment.
The recent introduction of a vaccine against hepatitis B has raised the questions of who should be offered it and what the cost would be of a vaccination programme. An analysis was performed of the financial costs and benefits of such a programme designed to prevent acute hepatitis B in male homosexuals in the United Kingdom. Under various assumptions the total costs of screening and vaccination ranged from 2.2m pounds to 3m pounds for a five year programme and from 3.3m pounds to 4.8m pounds for a 10 year programme. The benefits over the same two periods for the programme, depending on two different assumptions of mortality prevented, ranged 3.9m pounds to 13.7m pounds and from 7m pounds to 24.4m pounds. Thus considerable savings may be made to the national economy by offering vaccination to homosexuals. These savings are obtained after consideration of only the acute aspects of hepatitis B. Had it been possible to determine the costs of the chronic sequelae of this disease the savings, compared with the costs, would have been greatly increased.
Absenteeism↗
Genital herpes - the disease and its treatment including intravenous acyclovir.
This paper firstly reviews the natural history of genital herpes, giving special attention to the differences between primary and non-primary initial disease and recurrent disease and between herpes simplex virus 1 and 2. Secondly, previous therapies for genital herpes, and in particular the problems associated with previous drug trials are considered. The final part of the paper reviews a double-blind placebo controlled randomized study of intravenous acyclovir in patients with severe first attack, genital herpes. Intravenous acyclovir significantly reduced the duration of viral shedding, the healing time, the duration of vesicles and new lesion formation, and the duration of all symptoms, but did not prevent subsequent recurrences.
Acyclovir↗
Lymphogranuloma venereum of the rectum in a homosexual man. Case report.
A male homosexual presented initially with bloody diarrhoea and a swelling in the left groin, which was unsuccessfully treated with erythromycin. Examination in hospital showed a rectal mass and an abscess in the left groin. Histological examination of the rectal mass and a positive lymphogranuloma complement fixation test result confirmed the diagnosis of lymphogranuloma venereum. This disease, although rare, should not be forgotten in the differential diagnosis of rectal problems in male homosexuals.
Adult↗
Intravenous acyclovir in genital herpes. An interim report.
Twenty-five patients with primary genital herpes were treated in a double-blind placebo-controlled randomized trial of intravenous acyclovir. Thirteen patients received the drug and 12 a placebo. Three in each group were male. In the acyclovir group 10 patients had true primary herpes compared with six in the control group. The median time to healing of all lesions was significantly decreased from 11 to seven days (p less than 0.05), and the median duration of viral shedding from all lesions was decreased from eight to two days (p less than 0.001). The time to cessation of new lesions was decreased from a median of two days to zero days (p less than 0.001). Intravenous acyclovir is an effective treatment in decreasing the length and severity of primary genital herpes.
Acyclovir↗
Intravenous acyclovir treatment for primary genital herpes.
Explore the source record for details and available documents.
Acyclovir↗
Changing patterns of communicable disease in England and Wales.
Explore the source record for details and available documents.
Amebiasis↗
Growth hormone and somatomedin levels in acromegalics treated with bromocriptine.
Explore the source record for details and available documents.
Acromegaly↗
Coagulation studies in long-term survivors after renal allograft transplantation.
Screening coagulation studies were carried out on 69 long-term survivors who had received renal allografts. Fibrinogen levels were significantly raised in this group. Factor VIII activity was increased in 7 of the 11 patients studied. Six long-term survivors of renal allografts demonstrated arterial thrombotic phenomena. The onset of the thrombotic episode occurred at a relatively young age. It is considered that the hypercoagulable state may contribute to the observed increased tendency towards arterial thrombotic phenomena.
Adolescent↗